Intensity-Modulated Proton Therapy

PROCEDURE7 trials

Sponsors

Emory University, ECOG-ACRIN Cancer Research Group, M.D. Anderson Cancer Center, Mayo Clinic, Alliance for Clinical Trials in Oncology

Conditions

Astrocytoma, IDH-Mutant, Grade 3Biochemically Recurrent Prostate CarcinomaClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Cutaneous Squamous Cell Carcinoma of the Head and NeckHead and Neck CarcinomaHead and Neck Carcinoma of Unknown Primary

Early Phase 1

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

RecruitingNCT06914999

Emory UniversityClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 +13

Start: 2024-12-03End: 2027-08-31Target: 20Updated: 2025-10-22

Phase 2

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

WithdrawnNCT04834349

M.D. Anderson Cancer CenterRecurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma

Start: 2021-03-09End: 2022-11-21Updated: 2023-09-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

RecruitingNCT05075980

Mayo ClinicCutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary +9

Start: 2022-02-16End: 2035-11-15Target: 174Updated: 2026-02-13

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

RecruitingNCT05541016

Mayo ClinicClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 +4

Start: 2023-02-21End: 2029-08-01Target: 455Updated: 2025-11-04

Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

RecruitingNCT04423211

ECOG-ACRIN Cancer Research GroupBiochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma +1

Start: 2020-10-08End: 2032-12-31Target: 804Updated: 2026-04-03

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Not yet recruitingNCT07215910

Alliance for Clinical Trials in OncologyAstrocytoma, IDH-Mutant, Grade 3

Start: 2025-10-20End: 2040-01-31Target: 408Updated: 2025-10-14

Unknown Phase

Vertebral Body Sparing Craniospinal Irradiation for Pediatric Patients With Cancer of the Central Nervous System

CompletedNCT04276194

Emory UniversityMalignant Central Nervous System Neoplasm

Start: 2019-12-16End: 2024-02-09Updated: 2024-03-21

Related Papers

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology2023-06-011 citations

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology2023-02-20

Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology2021-05-203 citations

PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).

Journal of Clinical Oncology2021-02-202 citations